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Efficacy of Eculizumab in a Patient With Immunoadsorption-
Dependent Catastrophic Antiphospholipid Syndrome: A
Case Report
Andreas Kronbichler, MD, Renate Frank, MD, Michael Kirschfink, MD, A´gnes Szila´gyi, PhD,
Dorottya Csuka, PhD, Zolta´n Proha´szka, PhD, Peter Schratzberger, MD, Karl Lhotta, MD,
and Gert Mayer, MD
Abstract: Catastrophic antiphospholipid syndrome (CAPS) is a rare
but devastating complication in patients with antiphospholipid syn-
drome (APS) with a high morbidity and mortality.
We describe a case of a 30-year old female patient with immuno-
globulin A (IgA) deficiency who underwent splenectomy because of
idiopathic thrombocytopenic thrombocytopenia. Subsequently, an APS
and finally systemic lupus erythematosus was diagnosed. After an
uncomplicated pregnancy that was terminated by cesarean section,
the patient developed severe CAPS with cerebral, myocardial, renal,
and pulmonary involvement.
Because of IgA deficiency, standard therapy consisting of plasma-
pheresis and intravenous immunoglobulins in addition to steroids was not
tolerated. After 8 sessions of immunoadsorption (IAS), massive pulmon-
ary hemorrhage was controlled but relapsed twice whenever IAS was
terminated. As other immunosuppressive agents were considered danger-
ous because of the risk of infections in the face of severe hypogamma-
globulinemia, we administered eculizumab, an inhibitor of the terminal
complement pathway, which led to a persistent control of her disease.
Interestingly, eculizumab therapywas associated with a further decline of
complement C3 and C4 serum levels. The patient developed a subsequent
flare of her systemic lupus erythematosus, potentially indicating that
complement inhibition by eculizumab is not effective in preventing lupus
flares.
Taken together, we describe a unique case of life-threatening and
difficult-to-treat CAPS with a good clinical response after terminal
complement complex inhibition with eculizumab. Further controlled
trials are necessary to investigate the value of eculizumab in patients
with CAPS.
(Medicine 93(26):e143)
Abbreviations: CAPS = catastrophic antiphospholipid syndrome,
IAS = immunoadsorption, IgA = immunoglobulin A, IgG =
immunoglobulin G, IgM = immunoglobulin M, LDH = lactate
dehydrogenase, SLE = systemic lupus erythematosus.
INTRODUCTION
C atastrophic antiphospholipid syndrome (CAPS) is apotentially life-threatening and rare variant of the anti-
phospholipid syndrome (APS), characterized by vascular
thrombosis in, among others, the brain, lung, heart, and kidney,
ultimately leading to multiorgan failure. Most patients
develop antiphospholipid antibodies and thrombocytopenia
at the time of onset, whereas initially hemolytic anemia, dis-
seminated intravascular coagulation, and the presence of
schistocytes can be missing. Although diagnostic and thera-
peutic approaches improved over the last years, the morbidity
and mortality of patients with CAPS is still high.1 Pregnancy
and puerperium, per se predisposing to thrombotic events
because of the induction of a procoagulatory state, are well-
established triggers of the catastrophic variant,2 especially
when complicated by preeclampsia. Mutations of complement
regulatory proteins including membrane cofactor protein,
complement factor I, and complement factor H have also
been observed in patients with systemic lupus erythematosus
(SLE) and antiphospholipid antibody positivity.3
CASE REPORT
We report a 30-year-old woman, in whom splenectomy
was necessary because of idiopathic thrombocytopenic throm-
bocytopenia in 1997. Primary APS was diagnosed in 2004
after onset of deep venous thrombosis with antibodies against
anticardiolipin (>90U/mL, immunoglobulin M [IgM] and
immunoglobulin G [IgG] positive) along with anti-beta
2-glycoprotein (>90U/mL), and she finally fulfilled the diag-
nostic criteria of SLE4 in 2010 with predominance of muscu-
loskeletal and hematologic involvement. During her first
pregnancy, she was on antimalarial therapy with chloroquine
and low-molecular weight heparin because of APS. After
cesarean section and delivery in April 2013, confusion, acute
renal failure, myocardial ischemia with heart failure, severe
thrombocytopenia, and hemolytic anemia attributed to CAPS
developed. Dialysis was initiated and high-dose corticosteroid
therapy including initial bolus methylprednisolone (250mg
daily for 3 days) followed by oral methylprednisolone
(1.5mg/kg body weight), rituximab (1 g with a repeated admin-
istration after 4 weeks), and plasmapheresis was started. Plasma
exchange had to be stopped because of severe intolerance
reactions, which were attributed to a selective immunoglobulin
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A (IgA) deficiency, which also precluded high-dose intravenous
immunoglobulin therapy. The patient’s condition deteriorated
and she developed respiratory distress. A computed tomography
scan showed diffuse alveolar hemorrhage (Figure 1A). Immu-
noadsorption (IAS) therapy using the Life 18 (Miltenyi Biotec,
Bergisch Gladbach, Germany) was started with a total of
8 sessions. Treatment ameliorated thrombocytopenia and led
to a resolution of the lung injury (Figure 1B). However, the
patient was still dependent on dialysis. A renal biopsy revealed
typical microangiopathic injury. After recurrence of pulmonary
hemorrhage despite continuous high-dose methylprednisolone
therapy, 10 additional daily IAS sessions were performed with
clinical success. However, lung failure recurred again within
4 days after IAS withdrawal (Figure 1C) together with a rise in
lactate dehydrogenase, thrombocytopenia, anemia, and a schis-
tocyte count of 19 per mille. Thus, 4 additional sessions of IAS
were necessary to control the disease again (Figure 1D). Due to
low leukocyte counts and persistently low immunoglobulin
levels (IgG 37mg/dL and IgM 14mg/dL, respectively), cyto-
toxic therapy was considered dangerous because of the risk for
serious infections. It was, therefore, decided to administer
eculizumab, a monoclonal antibody against the complement
component C5, which prevents the activation of the terminal
complement pathway. Within 4 days, respiratory failure
completely resolved and signs of hemolytic anemia disappeared
despite cessation of IAS. Finally, therapeutic anticoagulation
with low molecular heparin could be commenced. The patient
was discharged dialysis dependent, but with increasing amounts
of urine 71 days after admission in July 2013 with a methyl-
prednisolone dosage of 60mg/day and on eculizumab treatment
(weekly administration of 900mg 4 times, followed by 1200mg
fortnightly). Laboratory values at the onset of the disease, after
3 weeks, at the time of eculizumab initiation, and after achieve-
ment of stable remission are depicted in Figure 2.
Two weeks after the discharge, the patient presented again
with signs of hemolysis after the fourth and fifth eculizumab
infusion. In addition, the serum levels of complement C3 and C4
were consistently reduced. Serum levels of both complement
components further declined in the days following eculizumab
infusion (data not shown). The patient received oral anticoagula-
tion with acenocoumarol. Eculizumab concentrations measured
prior and after application revealed efficacious serum concen-
trations, assured complete blockage of the terminal complement
pathway, and neutralizing antibodies could not be detected.
Addition of mycophenolate mofetil sufficiently abrogated hemo-
lysis, which was finally attributed to activity of the underlying
SLE, indicating a lack of efficacy of eculizumab in preventing a
lupus flare in this patient. The application of eculizumab could be
A B
C D
FIGURE 1. (A) Diffuse pulmonary hemorrhage in both lower lobes, which resolved after another initiation of (B) IAS. (C) After
discontinuation of IAS, recurrence of pulmonary hemorrhage could be detected. These findings prompted us to initiate yet another
series of IAS together with administration of eculizumab. (D) Complete resolution was detected in a control computed tomography 4 days
later. IAS ¼ immunoadsorption.
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stopped after 3 months in September 2013 after a total of 9
infusions without recurrence of thrombotic microangiopathy
despite a persisting positive test for antiphospholipid antibodies.
Several measurements of C3d and the terminal complement
complex (sC5bC9) while under treatment revealed normal serum
levels (data not shown). Examination of the complement regu-
latory protein factors H and I as well as the alternative pathway
component factor B revealed values within a normal range,
indicative of a normal alternative complement pathway. How-
ever, persistently reduced C3 and C4 serum levels along with a
low C1q (normal in one measurement and slightly reduced in
another) are suspicious for a consumption of the classical comp-
lement pathway (Table 1). In addition, to exclude inherited
predisposing factors in complement C3 or C4, genetic analysis
was performed. A rare heterozygous synonymous variation in
exon 13 of the C3 gene (c.1677C>T; p.C559C) was detected,
whichwas predicted as disease causingbyMutationTaster (http://
www.mutationtaster.org/) with a high probability (0.99)
(Table 2). Analysis of C4 revealed the presence of 2 copies of
the C4A and 1 copy of the C4B genes (data not shown).
One year after the initial insult, the patient is still dialysis
dependent. Steroid reduction was well tolerated without signs
of active thrombotic microangiopathy. The patient is listed
for renal transplantation. Her current medication consists of
mycophenolate mofetil 250mg twice a day, methylprednisolone
10mg every second day, blood pressure-lowering medication,
diuretics, thyroid hormone substitution, and acenocoumarol
with a target international normalized ratio of 2 to 3.
DISCUSSION
Eculizumab has already shown encouraging results in a
patient with recurrence of CAPS with reversal of thrombocy-
topenia and prevention of further clinical episodes of
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FIGURE 2. Laboratory values at the onset of the disease and at the time point of stable remission following eculizumab administration.
Reference values of the respective parameters: thrombocytes (150–380G/L), schistocytes (<5 per mille), and lactate dehydrogenase
(100–250U/L). Lactate dehydrogenase and schistocytes returned to normal values in the ninth week after onset time point and 4 weeks
after initiation of eculizumab.
TABLE 1. Complement Analysis After Application of Eculizumab and 6 mo After Cessation of Therapy
On Treatment With
Eculizumab (09/2013)
Off Treatment With
Eculizumab (02/2014)
Classical pathway (total complement activity) (range 48–103 CH50/mL) 0 39
Alternative pathway (total complement activity) (70%–105%) 1 67
Mannose-binding lectin pathway (0%–110%) 1 Not examined
C1q antigen (66–180 mg/L) 76 65
C2 (600–4000 CH63/mL) 1790 Not examined
C3 (0.9–1.8 g/L) 0.77 0.57
C3a (range 70–270 U/mL) 168 149
C4 (0.15–0.55 g/L) 0.07 0.09
sC5b9 (terminal pathway activation, range 110–252 U/L) 179 311
Factor H antigen (127–447 mg/L) 367 545
Factor I antigen (70%–130%) 88 85
Factor B antigen (70%–130%) 93 87
Anti-C1q autoantibody Negative
Anti-factor H IgG autoantibody Negative
IgG¼ immunoglobulin G.
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thrombosis.5 Its successful use has also been reported in recur-
rence of CAPS after renal transplantation.6,7 Transplantation in
CAPS is also possible with prophylactic eculizumab adminis-
tration.8 In addition, murine models reveal a pivotal role of the
complement system in antiphospholipid antibodies-induced
thrombosis along with endothelial cell and platelet activation.
Prevention of terminal complement formation by using a
monoclonal antibody against C5 inhibited thrombophilia
induced by antiphospholipid antibodies.9 Complement acti-
vation and consumption was also confirmed in our patient by
the finding that serum levels of C3 and C4 were significantly
lowered while disease was highly active. Immunohistochemical
analysis of the kidney biopsy specimen revealed a strong
staining for C1q and IgM, while deposition of C3, IgG, and
IgA was sparsely present. Interestingly, administration of ecu-
lizumab was associated with a further decrease in C3 and C4
serum levels. Moreover, sufficient eculizumab levels and comp-
lement inhibition was not capable of preventing a flare of her
underlying SLE. Evidence that eculizumab may not be effective
in SLE is still lacking, since there is limited data coming from a
phase I single-center trial. No changes in laboratory values and
systemic lupus erythematosus disease activity index have been
observed in this preliminary clinical trial. However, the cohort
of patients had low disease activity, thus precluding consider-
ations on the therapeutic efficacy of eculizumab.10
Our case confirms previous reports that it is possible to
discontinue eculizumab in CAPS after complete remission
despite a continuing positive test for antiphospholipid anti-
bodies. Persistently, reduced C4 and C3 levels in our patient
can be explained by continuous activation of the classical
complement pathway induced by immune complexes and
antiphospholipid antibodies that cannot be influenced by ecu-
lizumab. Furthermore, a lowered C1q serum level after ecu-
lizumab cessation and strong deposition in the kidney biopsy
also supports a consumption of the classical complement
pathway. The finding that eculizumab application was fol-
lowed by a further decrease in C4 and C3 serum levels is
intriguing. One possible explanation could be that eculizumab
interfered with clearance of immune complexes and thus
caused a further stimulation of the classical pathway. Genetic
analysis revealed a rare heterozygous variation in exon 13 of
the C3 gene. This mutation does not cause an amino acid
change in the C3 protein, so it is likely not causative; however,
a potential influence cannot be excluded, as its predicted
functional relevance showed a high probability as a disease-
causing factor.
CAPS remains a severe variant of the APS with a high
mortality rate of approximately 50%.1 However, patients
achieving disease control are prone to a persisting morbidity
as reported herein. This case is unique since the patient pre-
sented with a continuum of autoimmune disorders and had
underlying IgA deficiency. Due to the latter, the standard
therapy for CAPS was contraindicated or not tolerated by the
patient. The patient had a good clinical response toward IAS
combined with high doses of methylprednisolone, whereas she
was refractory to rituximab. Inhibition of the terminal comp-
lement pathway by eculizumab led to a persistent clinical
remission without evident recurrence of disease.
CONCLUSION
Targeting complement activation may provide a new
therapeutic option in the treatment of CAPS, especially in
patients refractory or unable to tolerate standard therapy. In
our exceptional case, stabilization of the disease course was
possible after eculizumab was commenced. Further clinical
investigations are necessary to clarify whether it can be gener-
alized that blockade of the terminal complement activation is
efficacious in the treatment of CAPS.
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